Author | Bryant Furlow

Genetics research shows great promise for personalized treatment in rheumatology - but diagnostic and prognostic gene tests are years away.

Tofacitinib and adalimumab improve physical function, pain, fatigue, well-being, emotional health and overall disease activity in patients with rheumatoid arthritis.

Both bone erosion and joint space narrowing are important indicators of physical disability in rheumatoid arthritis (RA), but measuring soft tissue damage not as relevant.

Researchers reporting in the journal Lupus find that a simple walking test can help assess the status of pulmonary disease in patients with systemic lupus erythematosus.

The choice of a biologic agent for treating rheumatoid arthritis (RA) may influence a patient’s risk of serious infections.